Wenhua Liang

Wenhua Liang


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
WGWei-Jie Guan
Wei-Jie Guan
ZNZheng-Yi Ni
Zheng-Yi Ni
YHYu Hu
Yu Hu
WLWenhua Liang
Wenhua Liang
COChun-Quan Ou
Chun-Quan Ou
NZNanshan Zhong
Nanshan Zhong
Since December 2019, when coronavirus disease 2019 (Covid-19) emerged in Wuhan city and rapidly spread throughout China, data have been needed on the clinical characteristics of the affected patients. We extracted data regarding 1099 patients with laboratory-confirmed Covid-19 from 552 hospitals in 30 provinces, autonomous regions, and municipalities in China through January 29, 2020. The primary composite end point was admission to an intensive care unit (ICU), the use of mechanical ventilation, or death. The median age of the patients was 47 years; 41.9% of the patients were female. The primary composite end point occurred in 67 patients (6.1%), including 5.0% who were admitted to the ICU, 2.3% who underwent invasive mechanical ventilation, and 1.4% who died. Only 1.9% of the patients had a history of direct contact with wildlife. Among nonresidents of Wuhan, 72.3% had contact with residents of Wuhan, including 31.3% who had visited the city. The most common symptoms were fever (43.8% on admission and 88.7% during hospitalization) and cough (67.8%). Diarrhea was uncommon (3.8%). The median incubation period was 4 days (interquartile range, 2 to 7). On admission, ground-glass opacity was the most common radiologic finding on chest computed tomography (CT) (56.4%). No radiographic or CT abnormality was found in 157 of 877 patients (17.9%) with nonsevere disease and in 5 of 173 patients (2.9%) with severe disease. Lymphocytopenia was present in 83.2% of the patients on admission. During the first 2 months of the current outbreak, Covid-19 spread rapidly throughout China and caused varying degrees of illness. Patients often presented without fever, and many did not have abnormal radiologic findings. (Funded by the National Health Commission of China and others.)

1 March 2020 in The Lancet Oncology
Verified
Journal Article
Closed access
WLWenhua Liang
Wenhua Liang
WGWeijie Guan
Weijie Guan
RCRuchong Chen
Ruchong Chen
WWWei Wang
Wei Wang
JLJianfu Li
Jianfu Li
JHJianxing He
Jianxing He

26 March 2020 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
WGWei-Jie Guan
Wei-Jie Guan
WLWenhua Liang
Wenhua Liang
YZYi Zhao
Yi Zhao
HLHeng-Rui Liang
Heng-Rui Liang
ZCZi-Sheng Chen
Zi-Sheng Chen
JHJianxing He
Jianxing He
Background: The coronavirus disease 2019 (COVID-19) outbreak is evolving rapidly worldwide.Objective: To evaluate the risk of serious adverse outcomes in patients with COVID-19 by stratifying the comorbidity status.Methods: We analysed data from 1590 laboratory confirmed hospitalised patients from 575 hospitals in 31 provinces/autonomous regions/provincial municipalities across mainland China between 11 December 2019 and 31 January 2020. We analysed the composite end-points, which consisted of admission to an intensive care unit, invasive ventilation or death. The risk of reaching the composite end-points was compared according to the presence and number of comorbidities.Results: The mean age was 48.9 years and 686 (42.7%) patients were female. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached the composite end-points. 399 (25.1%) reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD (HR (95% CI) 2.681 (1.424–5.048)), diabetes (1.59 (1.03–2.45)), hypertension (1.58 (1.07–2.32)) and malignancy (3.50 (1.60–7.64)) were risk factors of reaching the composite end-points. The hazard ratio (95% CI) was 1.79 (1.16–2.77) among patients with at least one comorbidity and 2.59 (1.61–4.17) among patients with two or more comorbidities.Conclusion: Among laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes.

1 March 2020 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
ZYZifeng Yang
Zifeng Yang
ZZZhiqi Zeng
Zhiqi Zeng
KWKe Wang
Ke Wang
SWSook-San Wong
Sook-San Wong
WLWenhua Liang
Wenhua Liang
JHJianxing He
Jianxing He
Background: The coronavirus disease 2019 (COVID-19) outbreak originating in Wuhan, Hubei province, China, coincided with chunyun, the period of mass migration for the annual Spring Festival. To contain its spread, China adopted unprecedented nationwide interventions on January 23 2020. These policies included large-scale quarantine, strict controls on travel and extensive monitoring of suspected cases. However, it is unknown whether these policies have had an impact on the epidemic. We sought to show how these control measures impacted the containment of the epidemic. Methods: We integrated population migration data before and after January 23 and most updated COVID-19 epidemiological data into the Susceptible-Exposed-Infectious-Removed (SEIR) model to derive the epidemic curve. We also used an artificial intelligence (AI) approach, trained on the 2003 SARS data, to predict the epidemic. Results: We found that the epidemic of China should peak by late February, showing gradual decline by end of April. A five-day delay in implementation would have increased epidemic size in mainland China three-fold. Lifting the Hubei quarantine would lead to a second epidemic peak in Hubei province in mid-March and extend the epidemic to late April, a result corroborated by the machine learning prediction. Conclusions: Our dynamic SEIR model was effective in predicting the COVID-19 epidemic peaks and sizes. The implementation of control measures on January 23 2020 was indispensable in reducing the eventual COVID-19 epidemic size.

1 August 2020 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
WLWenhua Liang
Wenhua Liang
HLHengrui Liang
Hengrui Liang
LOLimin Ou
Limin Ou
BCBinfeng Chen
Binfeng Chen
ACAilan Chen
Ailan Chen
FCfor the China Medical Treatment Expert Group for COVID-19
for the China Medical Treatment Expert Group for COVID-19
The outbreak of the novel coronavirus disease 2019 (COVID-19) began in Wuhan, China in December 2019. Since then, it has rapidly spread around the world. As of April 16, 2020, the WHO reported a total of 1 995 983 COVID-19 cases globally, with average mortality of 6.57%.

1 June 2020 in Cell
Verified
Journal Article
Closed access
KZKang Zhang
Kang Zhang
XLXiaohong Liu
Xiaohong Liu
JSJun Shen
Jun Shen
ZLZhihuan Li
Zhihuan Li
YSYe Sang
Ye Sang
GWGuangyu Wang
Guangyu Wang